What's happened to Dr. Stevenson formerly of Mott?
“I am pleased to join the Board of CDEX and look forward to working with my fellow directors to realize the full potential of CDEX’s life changing technologies. The company has developed valuable technology that could save thousands of lives every year through prevention of medication errors in the clinical environment. CDEX has a strong technology platform and vast market opportunity in healthcare and security both of which are key components for the future success of the Company. As a practicing pharmacist I recognize the prospects of the company and I will work to ensure that the best interests of shareholders, healthcare providers, and patients are represented on the board,” stated Dr. Stevenson.
“Dr. Stevenson brings additional expertise and credibility that correlates directly with the healthcare and clinical markets we are targeting for our ValiMed systems. His insight and healthcare industry relationships will be crucial to gaining market penetration for our fourth generation of the ValiMed™ Validation System. The ValiMed G4 raises the bar for patient medication safety and pharmaceutical drug loss prevention, providing cutting edge features and benefits over existing systems available in the market. The G4 identifies the drug, the dose, the diluents, and is the first system to feature multi-component compound detection. The G4 is able to perform non-invasive measures of compounds directly through IV bags, syringes and vials, offering lower risk of contamination with increased workflow. We look forward to working with Dr. Stevenson and the other directors towards the common goal of delivering life changing technologies to our customers and creating value for our shareholders,” stated Jeff Brumfield, CEO and Chairman of CDEX Inc.
AI
